13th Dec 2019 12:12
(Alliance News) - Drug development company ImmuPharma PLC on Friday said its shares will begin trading in Brussels next week as it eyes "additional visibility" among European investors.
On Thursday, Immupharma will list on Euronext Growth Brussels, Europe's largest market for life science firms, the company said.
Euronext Growth Brussels houses 106 life science companies, the index's head of listing said.
Immupharma said: "The dual listing on Euronext Growth Brussels aims to further increase the visibility of ImmuPharma's shares in continental Europe where the company is conducting its research & development activities in France and Switzerland.
"In addition to AIM, this dual listing on Euronext allows ImmuPharma to join the number one European stock exchange for life sciences and the world's second biggest for biotech companies after the United States."
The listing does not affect its trading on AIM and the company ruled out any fundraising plans on Euronext.
Chief Executive Dimitri Dimitriou said: "This dual listing on Euronext Growth Brussels gives ImmuPharma additional visibility among European investors. We are confident that our listing on Euronext Brussels will allow us to meet and develop relations with a community of new investors in continental Europe."
Shares in the company were 3.6% higher at 18.50p each in London on Friday shortly after midday.
By Eric Cunha; [email protected]
Copyright 2019 Alliance News Limited. All Rights Reserved.
Related Shares:
Immupharma